fda approved semaglutide Approves Oral as First GLP-1 Pill for Weight Loss FDA Approves Oral Semaglutide: First

This would indicate that any actions that reduce inflammatory processes will also reduce demands on the glutathione to quench the results of that inflammation and so higher concentrations will be available for other immune processes

But a large analysis of human head-and-neck cancer cases, conducted by the Mayo Clinic and published in 2025, debunked the link between GLP-1 drugs and thyroid cancer

Careful follow-up for weight in pediatric patients ages 6 to 12 years who received VYVANSE over 12 months suggests that consistently medicated pediatric patients (i.e., treatment for 7 days per week throughout the year) have a slowing in growth rate, measured by body weight as demonstrated by an age- and sex-normalized mean change from baseline in percentile, of -13.4 over 1 year (average percentiles at baseline and 12 months were 60.9 and 47.2, respectively)

The combination of protein and healthy fats found in these foods appears to be particularly effective at triggering GLP-1 release, while also providing essential nutrients like omega-3 fatty acids, vitamin E, and choline